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Abstract We have investigated whether poly(I:C) Toll-
like receptor 3 (TLR3) and resiquimod Toll-like receptor 7
(TLR7) agonists can serve as vaccine adjuvants and pro-
mote the efficiency of therapeutic DNA vaccination against
tumors expressing the human papilloma virus 16 (HPV-16)
E7 protein. For this purpose, C57BL/6 mice were inocu-
lated with 2 9 105 TC-1 cells, and they were then immu-
nized with HPV-16 E7 DNA vaccine alone or with 50 lg
of resiquimod or poly(I:C) individually. We found that
poly(I:C) and resiquimod could induce more antigen-spe-
cific lymphocyte proliferation and cytolytic activity com-
pared to vaccination with E7 DNA alone. While E7 DNA
had no significant inhibitory effect on tumor growth, co-
administration of poly(I:C) and resiquimod with E7 DNA
induced significant tumor regression. Peripheral and local
cytokine assays demonstrated that co-administration of
poly(I:C) and resiquimod with E7 DNA induced circulating
antigen-specific IFN-c and nonspecific intratumoral IL-12.
TLR3 and TLR7 agonists can be used to enhance the
immune response to DNA vaccine immunogens. Taken
together, these data indicate that combined vaccination
with DNA encoding HPV-16 E7 plus TLR agonists pro-
vides a strategy for improving the efficacy of a vaccine as a
possible immunotherapeutic strategy for cervical cancer.
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Introduction
Human papilloma viruses (HPVs) have been identified as
the etiological agents of cervical cancer, the second most
common malignancy in women worldwide [1]. The HPV
oncoproteins E6 and E7 are consistently expressed in HPV-
associated cancer cells and are responsible for their
malignant transformation [23, 24]. Several lines of evi-
dence suggest that cell-mediated immunity is important in
controlling both HPV infection and HPV-associated neo-
plasms [35]. Therefore, HPV E6 and E7 are ideal target
antigens for immunotherapy of HPV-induced lesions and
tumors.
The use of DNA vaccines has become an attractive
approach for the development of antigen-specific immu-
notherapy. The advantages of plasmid DNA immunization
are its ability to induce T-helper 1 (Th1) and CTL
responses, prolong antigen expression, and potentially
induce long-lived effector activity [18, 20]. One of the
concerns about DNA vaccines is their limited potency.
Therefore, ongoing research aims to augment the responses
to DNA vaccination through several mechanisms, includ-
ing co-administration of novel immunostimulants and
adjuvants [16, 17].
The use of adjuvants to improve vaccine efficacy is
typically feasible and cost-effective. Currently, the func-
tions of adjuvants are believed to be to activate innate
immunity, to increase the interaction between antigens, and
to modulate the intrinsic immunogenicity of an antigen
[30]. Chemical agonists of Toll-like receptors (TLR) are
now being considered as novel tools for screening potent
adjuvants for vaccine development [27]. The use of these
TLR agonists in vaccine formulations may permit the
development of effective therapeutic vaccine strategies for
the immunotherapy of cancer [3]. Several reports have
shown improved efficiency of vaccines in mice when
antigen delivery is combined with a TLR agonist [39].
Imiquimod and resiquimod (R848) are Toll-like receptor
(TLR) 7 and 8 agonists, and they are currently being
investigated as adjuvants in FDA-approved clinical trials
[10, 11]. These adjuvants have been shown to have
immune-response-modifying properties in vivo and to
induce antiviral and anti-tumor activity as well as stimu-
lating cytokine secretion in dendritic cells (DCs) [26].
Specifically, it has been demonstrated that resiquimod
activates the innate immune system via TLR-7 through the
activation of the MyD88 pathway in DCs. Activated DCs
are thought to follow a set program in which they secrete
inflammatory cytokines [14].
Polyinosinic-polycytidylic acid (poly(I:C)), a TLR3
agonist, is an artificial mimic of viral double-stranded RNA
and an interferon (IFN) inducer [21], and it has long been
known to be an antiviral agent. Toll-like receptor 3 pro-
motes cross-priming to virus-infected cells [4, 34].
Poly(I:C) can also serve as an effective adjuvant for
improving cellular immunity in response to vaccines [29,
32]. However, a detailed comparison of the efficiency of
these vaccine adjuvants has not been done, and there have
been no comparative studies in the DNA vaccine area.
Therefore, we compared the effects of co-administration of
resiquimod or poly(I:C) individually as Toll-like receptor
agonists with an HPV-16 E7 DNA vaccine and conclude
that the DNA vaccine in combination with resiquimod or
poly(I:C) induced a strong specific immune response with a
bias towards a Th1 immune profile. These combinations
also induced antitumor responses in a tumor microenvi-
ronment by increasing the level of pro-inflammatory T
helper 1 (Th1)-related cytokines and decreasing the level of
IL-10, a key factor required for tumor growth.
Materials and methods
Mice and cells
Female 6- to 8-week-old C57BL/6 mice were obtained
from the Institute Pasteur of Iran (Karaj, Iran). Mice were
housed for 1 week before the experiment, given free access
to food and water, and maintained in a light/dark cycle. All
experiments were carried out in accordance with the Ani-
mal Care and Use Protocol of Golestan University of
Medical Sciences of Iran.
The production and maintenance of TC-1 cells have been
described previously [13]. TC-1 cells were grown in RPMI
1640, supplemented with 10 % (v/v) fetal bovine serum, 50
units of penicillin/streptomycin per mL, 2 mM glutamine,
1 mM sodium pyruvate, 2 mM nonessential amino acids,
and 0.4 mg G418 per mL at 37 C with 5 % CO2.
DNA vaccine and adjuvants
The generation of pcDNA3-E7 has been described previ-
ously. Plasmid constructs were confirmed by DNA
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sequencing and expression. Amplification and purification
of DNA were described previously [12].
Resiquimod (1-(2-hydroxy-2-methylpropyl)-2-methyl-
1H-imidazo[4,5-c]quinolin-4-amine), formerly R-848) and
agonists of TLR3 (poly(I:C)) (InvivoGen) were dissolved
in PBS at a final concentration of 1 lg/ml and were
administered at a dose of 50 lg per subcutaneous (S.C.)
injection. PBS was administered as negative control using
the same schedule.
In vivo tumor treatment experiment
For in vivo therapeutic experiments, C57BL/6 mice were
divided into five groups (n = 10). The mice were chal-
lenged by subcutaneous (S.C.) injection in the right flank
with 2 9 105 TC-1 cells suspended in 100 ll PBS. After
one week, the mice were immunized S.C. in the right flank
with 90 lg of DNA vaccine encoding HPV-16 E7 three
times at 7-day intervals (group 1). In two groups, the
poly(I:C)-E7 DNA and resiquimod-E7 DNA, resiquimod
and poly(I:C) were dissolved in 100 ll PBS containing
90 lg of the pcDNA3-E7 construct and injected to each
mouse, using the same protocol, i.e., resiquimod or
poly(I:C) was administered S.C. in combination with
pcDNA3-E7 three times at 7-day intervals (resiquimod-E7
and poly(I:C)-E7 groups). PBS and pcDNA3 were injected
according to the same protocol into the fourth and fifth
groups of mice as negative controls (PBS and pcDNA3
groups).
Subcutaneous tumor volume was estimated according to
Carlsson’s formula [13]. Hence, the largest (a) and the
smallest (b) superficial diameters of the tumor were mea-
sured in a blinded, coded fashion twice a week, and then the
volume (V) of the tumor was calculated (V = a 9 b 9 b/2).
Statistical analysis was performed using Student’s t-test.
All values were expressed as mean ± S.D.
Three mice per group were sacrificed one week fol-
lowing the third immunization, and the spleens were
removed aseptically. Cell proliferation, cytolytic activity
and cytokine secretion were then assayed. All tests were
performed in triplicate for each mouse. Results are repre-
sentative of three independent experiments.
Lymphocyte proliferation assay (LPA)
One week after the third immunization, three mice per
group were sacrificed, and their splenocytes were isolated
and treated with ammonium chloride-potassium lysing
buffer for 1 min to deplete erythrocytes. In 96-well flat-
bottom culture plates (Nunc, Denmark) spleen cells
(2 9 105 per well) were cultured in triplicate with RPMI-
1640 supplemented with 10 % fetal calf serum, 1 %
L-glutamine, 1 % HEPES, and 0.1 % penicillin/
streptomycin and incubated in the presence of E7-specific
H-2Db CTL epitope at a concentration of 1 lg/ml (specific
antigen), T cell mitogen PHA (phytohemagglutinin, posi-
tive control), 2 lg of BSA per ml (irrelevant antigen) or
medium (negative control) at 37 C in 5 % CO2. After
3 days, MTT (3-(4,5-dimethyl tetrazolyl-2) 2,5 diphenyl-
tetrazolium bromide (Sigma Chemicals) at a concentration
of 5 lg/ml was added to each well and incubated for 5 h at
37 C in 5 % CO2. DMSO (dimethyl sulfoxide) (100 ll)
was added to dissolve formazan crystals that were
produced.
Plates were read at 540 nm, and the results were
expressed as a stimulation index (SI). The SI was deter-
mined as follows: OD value of stimulated cells (Cs) minus
relative number of unstimulated cells (Cu) divided by the
relative OD value of unstimulated cells.
SI ¼ (Cs  Cu)=Cu
All tests were performed in triplicate for each mouse.
CTL assay
One week after the third immunization, for each sample
obtained from an individual mouse (three mice per group),
a single cell suspension of mononuclear cells (used as the
effecter cells) was cocultured in RPMI 1640 medium with
washed EL4 target cells at a 50:1 effector-to-target cell (E/
T) ratio, at which maximal release of LDH was observed.
For preparation of the target cells, EL-4 cells were stimu-
lated with E7-specific H-2Db CTL epitope (E7, amino
acids 49–57) at a concentration of 1 lg/ml and then incu-
bated for 4 h.
After centrifugation, the supernatants (50 ll/well)
were transferred to 96-well flat-bottom plates, and lysis
of target cells were determined by measuring LDH
release using a Cytotoxicity Detection Kit (LDH)
according to the procedure recommended by the manu-
facturer (Takara). Several controls were used for the
cytotoxicity assay.
‘‘High control’’ was the total LDH released from the
target cells when all EL4 cells were lysed with medium
containing 1 % Triton X-100. ‘‘Low control’’ was the
natural release of LDH from the target cells, which was
obtained by adding only EL4 cells to the assay medium.
‘‘T-cell control’’ was used to measure the natural release of
LDH from T cells and was obtained by adding only dif-
ferent numbers of T cells to the assay medium. The assay
for all samples, including the controls, was performed in
triplicate.
The LDH-mediated conversion of the tetrazolium salt
into the red formazan product was measured at 490 nm
after incubation at room temperature for 30 min. The
Toll-like receptor agonist as DNA vaccine adjuvant 1953
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percentage of specific cytolysis was determined by the
following formula:
ððexperimental value  effector T cell controlÞ
 low controlÞ=ðhigh control  low controlÞ  100
Systemic cytokine assay
One week after the third immunization, mononuclear cells
from spleens of immunized mice at a concentration of
2 9 106 cells/well in 24-well plates (Nunc, Denmark) were
incubated for 2 days in a total volume of 1.5 ml of RPMI-
1640 supplemented with 10 % FCS, 1 % L-glutamine, 1 %
HEPES, 0.1 % 2ME, 0.1 % penicillin/streptomycin and
pulsed with E7-specific epitope (E7, amino acids 49–57) at
a concentration of 1 lg/ml at 37 C in 5 % CO2. The cell
supernatants were collected and assayed for the presence of
IFN-c and IL-4 using commercially available sandwich-
based ELISA kits (eBioscience, Inc., San Diego, CA) fol-
lowing the manufacturer’s instructions. All tests were per-
formed in triplicate for each mouse (three mice per group).
Intratumoral cytokine assay
Twenty-four hours after the last administration, TC-1
tumors were harvested and weighed, minced into small
pieces, and sonicated for 30 s in lysis buffer (PBS with 1 %
Triton-X, 1 mM phenylmethanesulfonyl fluoride [PMSF]:
1 mL of lysis buffer per 100 mg tumor). The samples then
were homogenized and centrifuged. The levels of IL-12
and IL-10 in tumor supernatants were measured using
commercially available sandwich-based ELISA kits
(eBioscience, Inc. San Diego, CA). The results are pre-
sented as the amount of cytokine (pg/mL) per 20 million
tumor cells.
Statistical analysis
Lymphocyte proliferation, CTL and cytokine assay were
analyzed by a one-way ANOVA. Significant differences in
tumor growth on given days were assessed by Student’s
t-test. Differences were considered statistically significant
when the P-value was less than 0.05.
Results
The co-administration of resiquimod and poly(I:C)
with E7 DNA vaccine enhances lymphocyte
proliferation
To determine whether the Toll-like receptor agonist influ-
enced the cell-mediated response, we performed antigen-
specific T cell proliferation assay in vitro. Splenocytes
were isolated from immunized mice, divided into four
parts, and stimulated with HPV-16 E7-specific CTL epi-
tope as a specific antigen, PHA as a positive control, BSA
as an irrelevant control, and medium as a negative control.
As shown in Fig. 1, lymphocyte proliferation was sig-
nificantly higher in mice treated with the DNA vaccine,
poly(I:C)-E7 DNA and resiquimod-E7 DNA than in the
negative control groups (PBS and pcDNA 3) (P \ 0.05).
Furthermore, the poly(I:C)-E7 DNA and resiquimod-E7
DNA groups exhibited significantly higher lymphocyte
proliferation than the group treated with E7 DNA without
adjuvants (P \ 0.01). The T cell proliferation response was
highest in the mice immunized with resiquimod-DNA
vaccine HPV-16 E7.
The co-administration of resiquimod and poly(I:C)
with E7 DNA vaccine enhances the CTL response
CTLs play a key role in the antitumor immune response
against cancers. In our study, the CTL response in immu-
nized mice was examined using the LDH release assay. As
shown in Fig. 2, the cytolytic activity was significantly
higher in mice treated with the DNA vaccine, the
poly(I:C)-E7 DNA and resiquimod-E7 DNA groups than in
the negative control groups (PBS and pcDNA 3)
(P \ 0.05). Furthermore, the poly(I:C)-E7 DNA and res-
iquimod-E7 DNA groups had a significantly higher anti-
gen-specific CTL response than the group treated with E7
DNA without adjuvants (P \ 0.001).
The co-administration of poly(I:C) with E7 DNA
vaccine shifts the cytokine pattern toward Th1,
but resiquimod-E7 DNA induces a mixed Th1 and Th2
response profile
Cellular immune responses were also evaluated by cyto-
kine secretion assay of the in vitro stimulated splenocytes
from all vaccinated animals. IFN-c secretion is a marker of
Th1-type antigen-specific cellular immune responses and
plays key roles in fighting cancer, while IL-4 is recognized
as Th2 biased.
The cytokine profiles induced by vaccination with E7
DNA were investigated following co-administration of
resiquimod and poly(I:C). As shown in Fig. 3, mice
immunized with the DNA vaccine produced significantly
more IFN- c and IL-4 than PBS- and pcDNA3-immunized
mice (P \ 0.05). Both IFN- c and IL-4 cytokines were
increased when resiquimod and poly(I:C) were co-admin-
istered with E7 DNA. With resiquimod and poly(I:C),
increases in IFN-c (indicative of Th1 responses) were
greater than those of IL-4 (indicative of Th2 responses).
Lymphocytes from the poly(I:C)-E7 DNA and resiquimod-
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Fig. 1 Splenocyte proliferation levels after in vitro stimulation with
an HPV-16 E7 epitope. C57BL/6 mice were challenged by subcu-
taneous injection of TC-1 cells. After one week, the mice were
immunized three times subcutaneously with poly(I:C)-E7 DNA,
resiquimod-E7 DNA, E7 DNA (test groups), and pcDNA3, and PBS
(negative control groups). One week after final immunization, spleens
of individual mice (n = 3) were removed, and lymphocyte prolifer-
ation was evaluated by the MTT method. Formazan crystal formation
after incubation with MTT was determined by dissolving the crystals
in DMSO, and optical density (OD) was read at 540 nm. All tests
were performed in triplicate for each mouse. Values are the
mean ± SD of the mean for the experiments. Lymphocyte prolifer-
ation of the poly(I:C)-E7 DNA and resiquimod-E7 DNA groups was
significantly higher than those in the control groups (P \ 0.05).
Results are representative of three independent experiments.
** Indicates statistically significant difference between the indicated
groups as determined by one-way ANOVA (P \ 0.01). The graph
also shows the statistically significant differences between all
treatment groups and the PBS and pcDNA3 control groups (P \ 0.05)
Fig. 2 Comparison of cytotoxic activity in mice vaccinated with
Toll-like receptor agonists as a DNA vaccine adjuvant. After mice
(n = 3) were immunized three times with the vaccines, spleens were
harvested as described in Materials and methods. Target cell lysis was
quantitated using an LDH release assay and expressed as percent
cytotoxicity ± SD. Results are representative of at least three
independent experiments. *** Indicates a statistically significant
difference between the indicated groups and those that received E7
DNA alone, as determined by one-way ANOVA (P \ 0.001). The
graph also shows the statistically significant differences between all
treatment groups and the PBS and pcDNA3 control groups (P \ 0.05)
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E7 DNA groups produced the largest amounts of IFN-c.
Furthermore, the combination of poly(I:C)-E7 DNA and
resiquimod-E7 DNA vaccine stimulated IFN-c production
more than E7 DNA vaccine alone (P \ 0.001). While the
combination groups had similar levels of IFN-c, the res-
iquimod-E7 DNA group produced significantly more IL-4
than mice immunized with the combination of poly(I:C)-
E7 DNA and DNA vaccine alone (P \ 0.001).
The co-administration of resiquimod and poly(I:C)
with E7 DNA vaccine drives the development
of intratumoural immunostimulatory cytokines
in a tumor microenvironment
Activation of antigen-specific CD8? T cells within spleens
is essential for broad tumor immunity, as the tumor sup-
pressive microenvironment may hinder T cell infiltration
into the tumor site or interfere with their anti-tumor
activity. Therefore, in order to assess the efficacy of the
adjuvant co-administration, the concentrations of immu-
nostimulatory and immuno-suppressive cytokines in the
tumor microenvironment were determined. We investi-
gated whether co-administration of resiquimod and
poly(I:C) with E7 DNA vaccine could induce cytokine
production in the tumor microenvironment. Mice with
established TC-1 tumors were therefore co-administrated
S.C. with toll-like receptor agonists and E7 DNA vaccine,
and the tumor was excised 24 h after the last injection.
After the extraction, the concentration of IL-12 and IL-10
were measured in the supernatant.
As shown in Fig. 4, mice immunized with the DNA
vaccine produced significantly more IL-12 but less IL-10
than PBS- and pcDNA3- immunized mice (P \ 0.05).
While IL-12 (indicative of immunostimulatory responses)
Fig. 3 Determination of the
ratios of TH1/TH2 cytokines by
enzyme-linked immunosorbent
assay (ELISA). Collected
supernatants (n = 3) from
stimulated splenocytes were
screened for the presence of
IFN-c and IL-4 to determine the
phenotypes of the immune
responses. The data are
presented as the mean ± S.D.
Each sample was examined in
triplicate. Results are
representative of three
independent experiments.
*** (P \ 0.001) indicates a
statistically significant
difference between the indicated
groups as determined by one-
way ANOVA. All treatment
groups show significant
differences when compared to
the negative control groups
(PBS and pcDNA3) (P \ 0.05)
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was increased when resiquimod and poly(I:C) were co-
administered with E7 DNA, IL-10 (indicative of immu-
nosuppressive responses) was decreased after the immu-
nizations. Tumor lysate from the poly(I:C)-E7 DNA and
resiquimod-E7 DNA groups produced the largest amounts
of IL-12. Furthermore, the combination of poly(I:C)-E7
DNA and resiquimod-E7 DNA vaccine stimulated IL-12
production more than E7 DNA vaccine alone (P \ 0.05).
Tumor lysate from the poly(I:C)-E7 DNA and resiquimod-
E7 DNA groups produced the smallest amounts of IL-10.
Furthermore, the combination of poly(I:C)-E7 DNA and
resiquimod-E7 DNA vaccine dampened IL-10 production
more than E7 DNA vaccine alone (P \ 0.01). These results
demonstrate that TLR agonists in combination with E7
DNA vaccine prevent a strongly immunosuppressive
milieu, which may be responsible for upregulating antitu-
mor responses and tumor regression.
Therapeutic co-administration of resiquimod
and poly(I:C) with E7 DNA cures mice with established
E7-expressing tumors
To determine whether the observed increase in E7-specific
immunity could be translated into a better E7-specific
antitumor effect, we performed an in vivo tumor treatment
experiment via a previously characterized E7-expressing
tumor model, TC-1.
We investigated whether co-administration of resiqui-
mod and poly(I:C) with E7 DNA vaccine could lead to
regression of preexisting tumors. For this purpose, 2 9 105
TC-1 cells were first injected S.C. into C57BL/6 mice in
the right flank. One week later, each mouse was treated
with E7 DNA, poly(I:C)-E7 DNA, resiquimod-E7 DNA,
control plasmid DNA or PBS three times at 7-day intervals.
The tumors were measured twice a week once they became
Fig. 4 Assessment of the levels
of pro-inflammatory and
immunosuppressive cytokines
in a tumor microenvironment.
C57Bl/6 mice were challenged
with 2 9 105 TC-1 tumor cells
and vaccinated as described in
the text. Twenty-four hours after
the last injection, animals were
sacrificed and homogenized to
form a uniform cell suspension.
The levels of IL-12 and IL-10 in
tumor supernatants were
analyzed by ELISA. Results are
representative of three
independent experiments with
three mice per group ± S.D.
*** (P \ 0.001) and
** (P \ 0.01) indicate
statistically significant
difference between the indicated
groups as determined by one-
way ANOVA. All treatment
groups show significant
differences when compared to
the negative control groups
(PBS and pcDNA3) (P \ 0.05)
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palpable. The tumor volume was monitored for 6 weeks
after the tumor challenge.
As shown in Fig. 5, in mice receiving resiquimod-E7
DNA and poly(I:C)-E7 DNA vaccinations, the TC-1
tumors were eliminated from 90 % and 80 % of mice,
respectively, whereas all of the mice receiving pcDNA3
plasmid or PBS developed tumors within 10 days after the
inoculation of TC-1 cells. Thus, the tumor volume was
significantly lower than in those in the pcDNA3 plasmid or
PBS group (p = 0.02).
For the mice receiving E7 DNA vaccination, 40 % of
those remained tumor-free 42 days after the TC-1 chal-
lenge. Additionally, the tumor volume in the resiquimod-
E7 DNA and poly(I:C)-E7 DNA groups were significantly
lower than that in the E7 DNA alone group (P \ 0.001). As
a control group, we also evaluated the antitumor effect of
pcDNA3 ? resiquimod or poly(I:C). The statistical ana-
lysis of tumor volume did not reveal significant differences
between these groups and the pcDNA3-alone group (data
not shown).
In summary, these results showed that co-administration
of resiquimod and poly(I:C) with E7 DNA could signifi-
cantly reduce tumor volume and eradicate the established
E7-expressing tumors, whereas vaccination with E7 DNA
alone failed to reduce established E7-expressing tumors in
mice. This indicated that resiquimod and poly(I:C) adju-
vants significantly promoted the antitumor immunity of the
DNA vaccine.
Discussion
The Toll-like receptor (TLR) superfamily plays a principal
role in the recognition of tumors and inducing immunity.
Thirteen human TLRs have been identified to date. Each
recognizes a distinct pathogen-associated molecular pattern
(PAMP), and upon specific ligand binding, they trigger an
antimicrobial innate immunity. Besides its involvement in
the innate immune response, TLR engagement by specific
ligands also shapes adaptive immunity [27].
Toll-like receptor agonists have been evaluated in
experimental models as adjuvants for cancer vaccines. The
basis of the therapy is that TLR agonists induce cell-
mediated immune responses, in particular Th1 cells, NK
cells and CD8 CTLs, which have been shown to promote
anti-tumor immune responses, but it has not been demon-
strated that the adjuvants eradicate tumor growth, although
recent reports of studies using mouse models suggest that
they may have some efficacy [3, 7].
To evaluate the antitumor activity of TLR agonists as
adjuvant in combination with a DNA vaccine, tumor
experiments were carried out to explore the potential
combinatorial use of TLR ligands in vaccine development.
In our study, mice were immunized subcutaneously with a
DNA vaccine encoding HPV-16 E7 together with TLR3
and TLR8 ligands. A previous study has demonstrated that
administering imiquimod and poly(I:C) in 20-lg doses was
not optimal for tumor clearance; therefore, we adminis-
tered the adjuvants at a dose of 50 lg per subcutaneous
injection [15]. Our results showed that the combination of
poly(I:C) (a TLR3 ligand) and resiquimod (a TLR7/8
ligand) with DNA vaccine synergistically induced signifi-
cant CD8? cytolytic activity, CD4? T cell proliferation
and interferon gamma secretion from pulsed lymphocytes
that were specific for the HPV-16 E7 antigen. In contrast,
there was little induction of CTL activity by delivery of
DNA vaccine encoding E7.
This is supported by previous findings that antigen-
specific CTL activity is induced by poly(I:C) [36, 37] and
resiquimod [26, 38] in nonhuman primates, supporting that
poly(I:C) and resiquimod co-delivery could be useful for
induction of antigen-specific CTL activity and cellular
immunity. Involvement of poly(I:C) [8] and resiquimod [5]
in the production of IFN-gamma has been reported
previously.
The responses indicated that resiquimod and poly(I:C)
as DNA vaccine adjuvants were able to induce cellular
immune response, which is critical in tumor eradication
[18, 22]. Cytokine secretion analysis revealed that the
cellular immune response could activate CTL to remove
tumor cells with E7 antigen [13].
Administration of these two ligands as adjuvant in the
E7-expressing tumor model TC-1 resulted in a reduction in
Fig. 5 In vivo antitumor effects generated by treatment with
poly(I:C)-E7 DNA, resiquimod-E7 DNA and E7 DNA alone.
C57BL/6 mice were inoculated subcutaneously with 2 9 105 TC-1
tumor cells. Mice were then treated with combinations of TLR
agonists and DNA vaccine as described in ‘‘Materials and methods’’.
Mice were monitored for tumor growth by measuring tumor diameters
with calipers twice a week. Line and scatter plot graphs depicting the
tumor volume (in mm3) are presented. The data presented represent
three independent experiments
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tumor growth. Furthermore, the tumor experiments showed
that combinational therapy led to tumor eradication in a
majority of the C57BL/6 mice. However, they were not
able to achieve complete tumor eradication in all animals
subjected to the treatment. Resiquimod-E7 DNA and
poly(I:C)-E7 DNA applications led to the regression of the
TC-1 tumor from 90 % and 80 % of mice, respectively,
while only 40 % regression was achieved in mice receiving
DNA vaccination alone. This is compatible with previous
findings of other groups. Dumitru et al. have demonstrated
that TLR7/8 activation by resiquimod can induce antitumor
effects through activation of antigen-presenting cell (APC)
function, infiltration of effector T lymphocytes and NK
cells with cytotoxic activity, and direct tumor-cell-specific
apoptosis [9]. In agreement with our antitumor findings, it
has been reported that poly(I:C)-induced apoptosis of
cancer is mediated through TLR3 expressed by tumor cells
[6, 31]. In other study for evaluation of poly(A:U) dsRNA,
a therapeutic effect was mediated through TLR3 expressed
on tumor cells, and this therefore represents an effective
targeted treatment in patients with TLR3-positive cancers
[33].
Intratumoral cytokine assays demonstrated that the
administration of TLR agonists with the DNA vaccine
results in substantial growth inhibition of pre-established
tumors in C57BL/6 mice.
Our results showed that the TLR-agonist-mediated anti-
tumor effect was associated with a significantly reduced
secretion of immunosuppressive mediators and cytokines
such as IL-10 and activation of the local immune regulators
such as Il-12.
In previous studies, it has been shown that poly(I:C)
stimulated monocyte-derived DCs to produce IL-12 and
decrease their production of IL-10 [2]. TLR8-specific
activation also induced IL-12 production by myeloid den-
dritic cells (mDCs) [19]. These activated DCs promoted
antigen-specific CTL responses and the differentiation of
CD4? T cells toward a Th1 phenotype [25]. The findings
are in accordance with our results showing that using TLR3
and 7 agonists as adjuvants skews the local intratumoral
immunity toward Th1 polarization.
A comparison of the adjuvants used in this study showed
that, in conjunction with resiquimod, the agonist even more
effectively induced antigen-specific cytotoxic CD8? T
cells and enhanced expression of Th2-associated cytokines
such as IL-4 against tumor challenge. It seems that there
still might be subtle differences in the adjuvant effects
between TLR3 and TLR7/8 agonists, although both even-
tually lead to similar levels of T cell activation. The TLR7/
8 agonist is more effective in inducing both cellular
immunity and regression of the tumor. Such divergence
may imply variable mechanisms in response to different
TLR ligands that may induce some different pathways [28].
For analysis of tumor control mechanisms, our results
demonstrated that the subsequent administration of a TLR
agonist with DNA vaccine will not only re-activate this
immune system in the periphery, in a nonspecific manner
against E7 antigen, but also mediate secretion of IL-12 as a
pro-inflammatory cytokine by tumor cells, resulting in
recruitment and intratumoral activation of effector cells.
The conjoint TLR agonist administration will occur in a
more efficient situation when a vaccine is first adminis-
tered, as the vaccine will induce tumor-specific immunity,
which will then be further re-stimulated and attracted to the
tumor microenvironment by TLR3 and TLR7/8 agonists.
Furthermore, after TLR treatment, tumor cells might also
become more recognizable and therefore more susceptible
to destruction by the immune system and display more
TLR signals and thus promote pro-apoptotic activity.
Therefore, the adjuvant activity of TLR agonists is due to
an immunostimulating effect, reversal of the immunosup-
pressive network in the tumor microenvironment, and
direct cytotoxic effect on tumor cells.
In conclusion, our study provides an outline for eradi-
cating HPV-induced cancers involving a combination of
poly(I:C) and resiquimod with an HPV DNA vaccine,
followed by the induction of peripheral and circulating
antigen-specific adaptive immunity and nonspecific intra-
tumoral innate immunity to promote antitumor immuno-
cytotoxic response to eradicate the lesions.
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